Cynvenio And Atgen Open Recruitment For New Liquidbiopsy Clinical Research Study In Triple Negative Breast Cancer

LOS ANGELES--(BUSINESS WIRE)--Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for all cancer patients and ATGen Global, a Korea-based biotech company, today announced the launch of a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer (TNBC) and show no radiographic signs of metastases.